Fig. 4: Oncolytic viruses improved the antitumour immune response of aPC by increasing the percentages of CD8+ T cells and memory T cells and reducing the percentage of Treg cells in peripheral blood and splenocytes. | Cancer Gene Therapy

Fig. 4: Oncolytic viruses improved the antitumour immune response of aPC by increasing the percentages of CD8+ T cells and memory T cells and reducing the percentage of Treg cells in peripheral blood and splenocytes.

From: Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model

Fig. 4

On days 8, 16, 21 and 24, peripheral blood cells were collected, and A the percentage of CD8+ T cells on days 21 and 24 as well as the ratio of CD8+ T cells to CD4+ T cells on day 24, B the percentage of memory T cells on days 21 and 24, C the percentage of Tregs on day 21 and D the percentage of TIE cells on day 24 were analysed by flow cytometry. At the endpoint, spleens were collected, and the immune phenotypes of the splenocytes were analysed as previously described. E The percentages of CD8+ T cells and Tregs at day 24 are shown. The data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus control; #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 versus aPC; &p < 0.05, &&p < 0.01 versus corresponding oncolytic viruses. One-way ANOVA followed by Bonferroni post hoc tests was performed.

Back to article page